Posted by Michael Wonder on 02 Mar 2020
Japan's national insurance to cover Novartis' gene therapy Zolgensma
26 February 2020 - Japan’s national insurance plans to cover Novartis’ gene therapy drug Zolgensma.
Zolgensma, used to treat spinal muscular atrophy, costs $2.1 million per treatment in the United States.
The drug has been approved for use by the Japanese government and discussions on pricing will be held by the Ministry of Health, Labor and Welfare, NHK reported.
